12:00 AM
 | 
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FG-3019: Phase II started

FibroGen began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3 or 10 mg/kg of intravenous FG-3019 given every 2 weeks...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >